Prognostic significance of the immunohistochemical reaction to human milk fat globule antibodies in node-negative and node-positive breast cancer
- 21 Downloads
The status of axillary lymph nodes in patients with breast cancer is important prognostically but does not identify all patients who will have long or short survival. To determine if the immunohistochemical reaction of tumor cells to human milk fat globule (HMFG) antibodies will define prognosis more specifically, we examined patients with node-negative disease and patients with more than three positive nodes, the extremes of the prognostic spectrum. In both node-negative and node-positive groups, patients who relapsed were matched by age at diagnosis, tumor size, histologic type, and receptor status, with patients who remained disease-free for a minimum of 48 months. Patients with poor survival had a higher proportion of poorly differentiated cancers. The ability to generate antigens recognized by HMFG antibodies was decreased in patients with recurrent disease, but this was significant only in patients with node-positive tumors. Tumors of patients who remained disease-free were more likely to have a pattern of membrane staining, while cytoplasmic staining was more frequent in those who relapsed. The results suggest that immunohistologic response to HMFG antibodies may assist in identifying cancers with poor prognosis, supplementing the prediction derived from node status.
Key wordsbreast cancer human milk fat globule antibodies immunohistochemistry prognosis
Unable to display preview. Download preview PDF.
- 7.Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319: 1681–1692, 1988Google Scholar
- 8.Rosner D, Lane WW, Nemoto T: Predicting disease-free survival in node-negative breast cancer patients: Do they need adjuvant therapy? Proc Am Assoc Cancer Res 30: A1008, 1989Google Scholar
- 9.Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouch R, Save-Soderbergh J, Holloway L, Russell I, Rudenstam CM: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58: 2662–2670, 1986PubMedGoogle Scholar
- 11.Andersen JA, Fischermann K, Hou-Jensen K, Henriksen E, Andersen KW, Johansen H, Brincker H, Mouridsen HT, Castberg Th, Rossing N, Rorth M: Selection of high risk groups among prognostically favorable patients with breast cancer: An analysis of the value of prospective grading of tumor anaplasia in 1048 patients. Ann Surg 194: 1–3, 1981PubMedGoogle Scholar
- 14.Taylor-Papadimitriou J, Millis R, Burchell J, Nash R, Pang L, Gilber J: Patterns of reaction of monoclonal antibodies HMFG-1 and -2 with benign breast tissue and breast carcinomas. J Exper Pathol 2: 247–260, 1986Google Scholar